(NASDAQ: INMB) Inmune Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.19%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.88%.
Inmune Bio's earnings in 2025 is -$55,508,000.On average, 1 Wall Street analyst forecast INMB's earnings for 2025 to be -$35,624,246, with the lowest INMB earnings forecast at -$35,624,246, and the highest INMB earnings forecast at -$35,624,246. On average, 1 Wall Street analyst forecast INMB's earnings for 2026 to be -$34,294,983, with the lowest INMB earnings forecast at -$34,294,983, and the highest INMB earnings forecast at -$34,294,983.
In 2027, INMB is forecast to generate -$37,219,361 in earnings, with the lowest earnings forecast at -$37,219,361 and the highest earnings forecast at -$37,219,361.